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Abstract
Leishmania spp. are a medically important group of protozoan parasites that synthesize a novel intracellular carbohydrate
reserve polymer termed mannogen. Mannogen is a soluble homopolymer of b-1,2-linked mannose residues that
accumulates in the major pathogenic stages in the sandfly vector and mammalian host. While several steps in mannogen
biosynthesis have been defined, none of the enzymes have been isolated or characterized. We report the development of a
simple assay for the GDP-mannose–dependent b-1,2-mannosyltransferases involved in mannogen synthesis. This assay
utilizes octyl a-D-mannopyranoside to prime the formation of short mannogen oligomers up to 5 mannose residues. This
assay was used to screen a focussed library of 44 GMP-triazole adducts for inhibitors. Several compounds provided effective
inhibition of mannogen b-1,2-mannosyltransferases in a cell-free membrane preparation. This assay and inhibitor
compounds will be useful for dissecting the role of different mannosyltransferases in regulating de novo biosynthesis and
elongation reactions in mannogen metabolism.
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Introduction
Leishmania spp are sandfly-transmitted protozoan parasites that
cause a spectrum of diseases in humans, ranging from localized,
self curing skin lesions (cutaneous leishmaniasis) to disseminating
infections of the facial mucosa (mucocutaneous leishmaniasis) and
the liver and spleen (visceral leishmaniasis or Kala Azar) [1]. It is
estimated that 1.5–2 million people develop symptomatic disease
each year resulting in more than 70,000 deaths and an infection
prevalence of 12 million people worldwide [2]. There are no
defined vaccines for human leishmaniasis and current front-line
drug treatments, such as pentavalent antimony and miltefosine,
are inadequate due to toxicity and/or expense and are being
undermined by the emergence of drug-resistant parasite strains
[2]. For these reasons there is a pressing need to identify new
therapeutic targets in these parasites and drugs with greater
specificity and efficacy.
Leishmania are transmitted to humans and other mammalian
hosts via the bite of female sandfly vectors (of genera Lutzomyia and
Phlebotomus). The parasites develop as flagellated promastigote
stages in the digestive tract of the sandfly vector and infective (non-
dividing) promastigotes injected into the skin during the sandfly
bloodmeal are rapidly internalized by phagocytic host cells, such
as neutrophils and macrophages. Internalized promastigotes are
delivered to the phagolysosome compartment of macrophages and
differentiate to the non-motile amastigote stage that is responsible
for perpetuating disease in the mammalian host. Significant
progress has been made in identifying metabolic pathways that are
essential for parasite survival in macrophages and the establish-
ment of acute and chronic infections [3]. Several pathways have
been shown to differ significantly from comparable pathways in
the mammalian host. In particular, Leishmania spp. synthesizes a
unique carbohydrate reserve material termed mannogen [4,5], a
homopolymer of b-1,2-linked mannose, 4–40 residues long that is
freely soluble in the cytoplasm [5]. Mannogen can be assembled de
novo on a novel mannose-1,4-cyclic-phosphate primer, or by
elongation of existing oligomers by non-processive guanosine-
diphospho- (GDP)-mannose–dependent b-1,2-mannosyltrans-
ferases (Figure 1A) [5]. While the precise role of mannogen in
parasite infectivity is not known, Leishmania mutants with global
defects in mannose metabolism are unable to infect macrophages
or survive in highly susceptible animal models [6,7]. Moreover,
pathogenic promastigote and amastigote stages that initiate and
perpetuate infection, respectively, accumulate high levels of
mannogen [4]. Taken together, these observations suggest that
mannogen is likely to be important for infectivity in the
mammalian host and that enzymes involved in its synthesis and/
or degradation are potential drug targets.
The development of specific in vitro assays for mannogen
biosynthetic enzymes is an essential prerequisite for the purifica-
tion of enzymes involved in de novo synthesis and mannogen
elongation and the identification of corresponding genes, none of
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to distinguish between the mannogen-specific b-1,2-mannosyl-
transferases and other parasite a-mannosyltransferases that
catalyze the synthesis of dolichol-linked oligosaccharides leading
to N-linked glycans [8] and glycosylphosphatidylinositol glycolip-
ids [9,10]. While there is evidence that the N-linked glycan
biosynthesis pathway is required for Leishmania virulence [6], this
pathway is largely conserved from Leishmania to humans with
similar a-mannosyltransferases present in both organisms [11],
and achieving specificity for the Leishmania enzymes could prove
challenging. Thus specific inhibitors of the parasite-specific
mannogen b-mannosyltransferases would be useful biological
probes with which to study the functional significance of
mannogen biosynthesis. Using a combinatorial approach, we have
previously demonstrated that mannosides bearing a wide range of
substituents were able to act as substrates for these enzymes [12].
Based on these results, we show that octyl a-D-mannopyranoside
can function as a primer for the assembly of short mannogen
chains and be used to measure b-1,2-mannosyltransferase activity
in crude parasite extracts. We also describe the use of this assay to
screen for potential inhibitors of this pathway. The development of
glycosyltransferase inhibitors has generally been considered a
difficult proposition [13,14,15]. Although there are some natural
product inhibitors available [16,17,18], and several glycosyltrans-
ferase inhibitors are in use as drugs (eg ethambutol, caspofungin,
N-butyldeoxynojirimycin) and veterinary products (lufenuron,
moenomycin), most rationally-designed glycosyltransferase inhib-
itors suffer from demanding chemical syntheses and poor activity,
and few strategies that provide general approaches to inhibitors of
new glycosyltransferase classes have been elaborated. A promising
approach has been pioneered by the groups of Tabak and Bertozzi
[19], and Wong and Sharpless [20] wherein a focussed library
based on modification of the nucleoside/diphosphonucleotide of
the donor has provided powerful inhibitors of murine polypeptide
N-acetyl-a-galactosaminyltransferase and human a-1,3-fucosyl-
transferase, respectively. Only a few effective mannosyltransferase
inhibitors have been reported [15,21,22,23,24,25] and the
strategies utilized for their discovery lack the generality of the
Figure 1. Biosynthesis of Leishmania spp. mannogen and strategy for combinatorial discovery of mannosyltransferase inhibitors. A)
Biosynthesis of mannogen in Leishmania mexicana parasites. De novo biosynthesis commences from mannose-1-phosphate and proceeds via a cyclic
phosphate primer (ManPc). Elongation of the primer followed by its removal affords oligomers of 4–40 mannose residues. These can be catabolised
to release monomeric mannose units and the shortened oligomers re-extended. B) General approach used for the construction of a GMP-focussed
combinatorial library and screened against L. mexicana b-1,2-mannosyltransferases.
doi:10.1371/journal.pone.0032642.g001
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Wong/Sharpless groups. Using a related combinatorial approach,
we show here that several GMP analogues can inhibit the activity
of the leishmanial b-1,2-mannosyltransferases in crude microsomal
extracts (Figure 1B).
Results
Assay development
Based on the observation that the Leishmania mexicana b-1,2-
mannosyltransferases demonstrated a wide tolerance for a range of
anomeric substituents on the mannose acceptor [12] we
synthesized a simple hydrophobic substrate, octyl a-D-mannopyr-
anoside 1 [26] (Figure 2A). As the genes for the Leishmania
mannosyltransferases have not been identified, we were limited to
using endogenous enzyme isolated as a membrane preparation
from the parasite. For convenience, we utilized a parasite strain
containing a targeted deletion of the gene encoding GDP-mannose
pyrophosphorylase (L. mexicana Dgmp) [6]. This strain lacks the
enzyme GDP-mannose pyrophosphorylase (responsible for syn-
thesis of GDP-mannose from mannose-1-phosphate and guano-
sine triphosphate (GTP)), and lacks endogenous pools of manno-
gen that could act as alternative acceptors. Moreover, we have
found that GDP-mannose pyrophosphorylase primarily catalyzes
the conversion of GDP-mannose to mannose-1-phosphate and
GTP in cell lysates resulting in the rapid hydrolysis of GDP-
[
3H]mannose used as the donor in our assay. Incubation of 1 with
GDP-[
3H]mannose and cell extracts from L. mexicana Dgmp
resulted in robust radiolabelling of several lipidic species that
were efficiently recovered by water-butanol phase partitioning
(Figure 2B). Products arising from a-linked mannoside acceptors
are sensitive to digestion by snail b-mannosidase, but insensitive to
jack bean a-mannosidase, and structural analysis by methylation,
followed by hydrolysis, reduction and acetylation, and GC-MS
revealed these to be exclusively b-1,2-linked mannose oligomers
[12]. These results show that synthetic octyl a-D-mannopyranoside
1 can act as a primer for one or more b-1,2-mannosyltransferases
and was used in all subsequent biochemical assays.
By careful selection of reaction conditions, octyl a-D-mannopyr-
anoside 1 could be used to determine indicative kinetic parameters
for reactions using GDP-[
3H]mannose and crude L. mexicana Dgmp
membranes by quantification of the radiolabelled product
disaccharide by HPTLC. To determine kinetic parameters for
GDP-mannose, octyl a-D-mannopyranoside 1 was used at a
constant concentration of 50 mM. At concentrations below 8 mM
of GDP-mannose, more than 10% of the donor was consumed,
and so unreliable rate data was generated. At GDP-mannose
concentrations of 8 mM and above, trisaccharide product is
formed, however levels were at or below 10% of the quantities of
disaccharide and so could be ignored for rate calculations.
Figure 2C shows a Michaelis-Menten plot of data obtained within
the limits outlined above, allowing determination of a crude KM
value for GDP-mannose of 1.0 mM and Vmax of 1.8 mMs
21. This
KM value is surprisingly high for a glycosyltransferase enzyme, and
might reflect the fact that mannogen is involved in central energy
metabolism and so substantial flux to both form and degrade this
metabolite might be required at various stages in the parasite
lifecycle and in response to stresses, suggesting that it has evolved
to operate at high GDP-mannose concentrations. Similarly, to
determine kinetic parameters of octyl a-D-mannopyranoside 1,
GDP-mannose was used at a constant concentration of 10 mM.
Once again careful selection of reaction conditions to ensure less
than 10% consumption of the donor and formation of less than
10% trisaccharide relative to disaccharide provided Michaelis-
Menten parameters for octyl a-D-mannopyranoside 1 of
KM=4.3 mM and Vmax=2.3 mMs
21 (Figure 2D). In this case a
millimolar KM value might reflect the fact that the mannogen
substrate is found at millimolar concentrations within pathogenic
promastigote and amastigote stages [4]. It should be emphasized
that these kinetic parameters do not represent the true parameters
for enzymatic catalysis owing to the use of impure enzyme extracts
that may contain more than one b-1,2-mannosyltransferase
activity, and activating or inhibitory components that may affect
accurate determination of true reaction rates. While mannogen-
catabolising enzymes could also influence the apparent rate of
synthesis, we found no evidence that [
3H]-labeled, octyl-manno-
sides were degraded under the assay conditions. These data can
thus be used to define assay conditions to determine inhibitor
potency (vide infra).
Library design
To define a suitable starting point for library construction, we
qualitatively assessed the inhibition of b-1,2-mannosyltransferase
activity by both guanosine diphosphate (GDP, the product of
Figure 2. Characterization of b-1,2-mannosyltransferase activ-
ity and inhibition. A) Extension of octyl a-D-mannoside by L.
mexicana Dgmp b-1,2-mannosyltransferases. B) Fluorogram of
HPTLC of 0.05 mM octyl a-D-mannopyranoside incubated with GDP-
[
3H]mannose in a membrane preparation of L. mexicana Dgmp with
GDP-[
3H]mannose; C) Michaelis-Menten plot (inset: Lineweaver-Burke
replot) of rate versus [GDP-mannose] at saturating (50 mM) octyl a-D-
mannopyranoside; D) Michaelis-Menten plot (inset: Lineweaver-Burke
replot) of rate versus [octyl a-D-mannopyranoside] at saturating
(10 mM) GDP-mannose; E) Fluorogram of HPTLC showing inhibition
of b-1,2-mannosyltransferase-catalyzed extension of octyl a-D-manno-
pyranoside by GMP and GDP. M2–5 denote the oligomer length of
oligomannosides formed from the substrate.
doi:10.1371/journal.pone.0032642.g002
Leishmania b-1,2-Mannosyltransferase Inhibitors
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32642transfer of mannose from GDP-mannose) and the nucleotide
guanosine monophosphate (GMP). L. mexicana Dgmp membranes
containing b-1,2-mannosyltransferases were isolated by centrifu-
gation and incubated with octyl a-D-mannopyranoside 1, GDP-
[
3H]mannose, and either GMP or GDP (at 0.1–10 mM)
(Figure 2E). Both nucleotides showed substantial inhibition of
oligomannoside synthesis at the highest concentration (10 mM),
with inhibition being greatest for GMP. Accordingly, we based our
library design on structural modification of GMP. Inspired by the
approach of Wong and Sharpless [20], we elected to install a
terminal alkyne as part of a propargyl ester with the phosphate of
GMP, and then to explore substituent variation through
modification with a range of azide derivatives.
Synthesis of GMP-alkyne
As preliminary attempts to install a propargyl group through
direct esterification of GMP were unsuccessful, we resorted to a
route that used protecting groups on the nucleoside guanosine
(Figure 3). Unwanted phosphatitylation of the guanine nucleobase
is problematic mainly during the synthesis of oligonucleotides
[27,28,29], and it was therefore deemed unnecessary to protect the
guanine group [30]. A TBDMS group was selected for protection
of the 29- and 39-hydroxyls of the ribose as TBDMS ethers can be
cleaved using TBAF in tandem with a cyanoethyl protecting
group, a useful protecting group for phosphate. The primary
alcohol 2 was prepared according to Scott and co-workers [31],
and the phosphate group was introduced via the phosphorodia-
midite (
iPr2N)2POCH2CH2CN [32], which was synthesized in a
one-pot reaction from PCl3, 2-cyanoethanol and diisopropylamine
[33]. (
iPr2N)2POCH2CH2CN can be selectively activated for
coupling to alcohols using the weak acid catalyst diisopropylam-
monium tetrazolide (DIPAT) [34]. Under these conditions only
the monotetrazolide is generated, and the phosphoramidite
formed after coupling to an alcohol is inert to activation by
DIPAT [35]. Accordingly, the alcohol 2 afforded the phosphor-
amidite 3 in a 46% yield. Treatment of 3 with propargyl alcohol
and 1H-tetrazole for a brief period, followed by oxidation using I2
in H2O/pyridine/THF (0.1 M, 2:20:80) gave the protected alkyne
4 in an acceptable yield of 57%. Global deprotection of 4 by
treatment with TBAF in THF gave the alkyne 5, which was
purified by HPLC and ion-exchange chromatography in 37%
yield.
Azide diversity set
We have previously reported the synthesis of an extensive azide
diversity set obtained from amines of differing hydrophobicity and
hydrogen-bonding potential through acylation with v-bromoacyl
chlorides and subsequent azide substitution [12]. This set of
compounds was complemented with an additional 26 azides from
Chemical Block (Moscow) to give a diversity set of 47 azides (A01–
A47; for structures see Figure S1). Notably, this library contains
the azide A08, which was utilized by Sharpless and Wong in the
discovery of a nanomolar GDP triazole-linked inhibitor of a-1,3-
fucosyltransferase, compound 6 [20].
Library construction
Our initial attempts to generate a combinatorial library through
a standard CuAAC reaction protocol using CuSO4 and sodium
ascorbate in the presence of the Cu
I-stabilizing ligand TBTA was
unsuccessful [36]. presumably owing to inhibitory complexation of
soluble copper species by the guanosine nucleobase. Instead we
resorted to a protocol that used CuSO4 and copper metal to
generate a constant supply of Cu
I by comproportionation.
Mixtures of alkyne 5, azide A01, CuSO4 and copper shavings,
with and without TBTA, were stirred for 24 h and the reaction
mixtures analysed by HPLC-MS. Gratifyingly, both reactions
were shown to have proceeded to completion after 24 h, and so
the addition of TBTA was deemed unnecessary. Using the TBTA-
free conditions, the remaining azides A02–A47 were coupled to
the alkyne 5. HPLC-MS analysis of the reaction mixtures revealed
that all but three had proceeded to completion, with the expected
triazole adducts T01–T24, T26–T38, T40 and T42–47 being
observed (Table S1). In the cases of A25, A39 and A41, while the
alkyne had been consumed, the expected products T25, T39 and
T41 were not observed. On this basis, these failed reactions were
excluded from further studies.
Screening of the combinatorial library for inhibitors
As our previous studies had demonstrated that low levels of Cu
II
have no effect on biosynthesis of mannogen [12], the products
were not purified. Instead, the mixtures were concentrated to
dryness and resuspended in 80% DMSO/H2O to give 25 mM
stock solutions. Initial screening was conducted using a high
concentration of library compounds to allow the identification of
even weak inhibitors. Putative inhibitors at 4 mM were incubated
Figure 3. Synthesis of GMP-alkyne. a) (
iPr2N)2POCH2CH2CN, diisopropylammonium tetrazolide, CH2Cl2,0 uCRrt, 75 min, 46%; b) i 1H-tetrazole,
propargyl alcohol, CH2Cl2,0 uCRrt, 15 min; ii 0.1 M I2 in H2O/pyridine/THF (2:20:80), 10 min, 57%; c) 1.0 M TBAF/THF, 45 min, Dowex 50W-X4 (Na
+
form), 37%; d) Cu
0, CuSO4, DMSO/H2O (9:1), 50%.
doi:10.1371/journal.pone.0032642.g003
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(40 mM), GDP-[
3H]mannose (50 mM) and L. mexicana Dgmp cell
membranes. With the exception of T40, all compounds were
capable of inhibiting the mannosylation of octyl a-D-mannopyr-
anoside to at least some degree. Some interesting trends were
apparent, for example the homologues T04 and T05, and the
series T14–T16 displayed similar activities. On the other hand
other structurally-related triazole pairs, such as T07/T08, T21/
T22, T44/T45, and T46/T47 displayed surprisingly different
activities.
In order to discriminate among the more active inhibitors
identified in the first screen a second round of assays was
conducted as per the first, however this time inhibitors were used
at a lower concentration of 1.27 mM. As shown in Figure 4, a
lower concentration of inhibitor allowed differences in inhibition
levels to be observed. Compounds T14, T33, T38 and T47 were
among the best inhibitors of the set, with T47 exhibiting the
greatest inhibition, almost completely ablating the synthesis of
mannogen oligomers. Notably, under the conditions of this assay,
greater inhibition of mannogen oligomers was observed for T47
versus GMP.
In order to further characterize the biological activity of T47,
this compound was resynthesized and purified by HPLC. Using
the assay conditions developed for study of the kinetic parameters
of octyl a-D-mannopyranoside, more detailed kinetic parameters
were determined for T47, and for comparison purposes, GMP.
We elected to use a relatively high concentration of both octyl a-D-
mannopyranoside 1 (17 mM, 46 Km) and GDP-[
3H]mannose
(3.5 mM, 46 Km), conditions that constitute a stringent test for
effective inhibition. Each inhibitor was incubated at a range of
concentrations (0.09–11.2 mM) with L. mexicana Dgmp membranes
for 4 minutes at 27uC. By reducing the duration of the reaction it
was possible to limit trisaccharide formation to low levels. The
incorporation of radioactivity into disaccharide was measured at
each inhibitor concentration, and curves were fitted to the data
using nonlinear regression, giving IC50 values of 2.7 mM for T47
and 2.6 mM for GMP (Figure 5).
Discussion
Current evidence suggests that enzymes involved in mannogen
biosynthesis and degradation are potential targets for new anti-
Leishmania therapeutics. Here we describe the development of a
simple in vitro assay for the mannogen-specific b-1,2-mannosyl-
transferases. This assay utilizes the readily synthesized hydropho-
bic primer, octyl a-D-mannopyranoside 1 as acceptor and GDP-
[
3H]mannose as mannosyl donor. The octyl-mannoside product
containing short b-1,2-mannose chains can be conveniently
isolated by partitioning with butanol/water and separated by
HPTLC. In this work we applied this assay to the development of
b-1,2-mannosyltransferase inhibitors.
Rational approaches to inhibition of glycosyltransferases include
metabolic interference approaches such as use of alternative
acceptor substrates as decoys [37], and feeding approaches to
generate dead-end acceptor mimics [24,38]. Significant effort has
been expended on the synthesis of substrate analogues of the
enzymatic transition state [13,39]. An alternative strategy is to
modify either the donor [40,41,42] or acceptor [43] substrates in
ways to either prevent transfer or to introduce substituents that can
take advantage of adventitious binding in the enzyme active sites.
One notable recent publication utilized the cellular biosynthetic
machinery to transform a synthetic carbohydrate precursor into an
inhibitory sugar nucleotide analogue [44]. Random screening
approaches have yielded some inhibitors of glycosyltransferases,
however, large number of compounds are required [45,46,47,48].
On the other hand targeted combinatorial approaches using
relatively small libraries based on modifying the nucleoside
fragment of the glycosyl donor has yielded significant success in
inhibitor discovery of glycosyltransferases [19,20]. While the
original ‘click chemistry’ approach to inhibitors of a-1,3-
fucosyltransferase commenced with GDP as a starting point
owing to its favourable binding characteristics toward the target
enzyme [20], our study commenced with GMP as it was identified
as a more effective inhibitor than GDP of the GDP-mannose–
dependent b-1,2-mannosyltransferases of L. mexicana.
Screening of a library of 44 GMP-triazole adducts revealed an
inhibitor of the target b-1,2-mannosyltransferases with an IC50
value of 2.7 mM. While the IC50 value of T47 is similar to that of
GMP (IC50=2.6 mM), this result is significant for several reasons.
GMP is a substrate for a range of enzymes including phosphatases
and pyrophosphorylases, which means that it is not a stable species
in biochemical studies in crude cell extracts, being rapidly
converted by metabolic processes. T47 is sufficiently stable to
show inhibition in a membrane preparation of L. mexicana and as a
phosphodiester may possess greater stability for cell-based studies
relative to GDP or GMP. As well, it possesses a single negative
charge and a large lipophilic anthraquinone structure, suggesting it
may have greater cell permeability than GMP or GDP, possibly
allowing its use in cell culture. While this inhibitor is unlikely to be
useful as a therapeutic agent, it represents a useful starting point
for further structural optimization. Our screening study showed
that a range of different structures within the library of compounds
possessed significant inhibitory activity, suggesting that it may be
possible to further improve inhibitory activity by systematic
structural optimization. Interestingly, T08, derived from the same
azide component (A08) as the most effective GDP-based inhibitor
6 of human a-1,3-fucosyltransferase [20], did not provide the most
effective inhibition in this library of compounds, suggesting that
T47 may have some selectivity for the leishmanial b-1,2-
mannosyltransferases (Figure 6). In the absence of genetic
information allowing the targeted deletion of genes involved in
mannogen biosynthesis within the leishmania parasite, T47
represents a useful biochemical tool for further dissection the role
of different mannosyltransferases in the mannogen metabolic
pathway.
Materials and Methods
1. Chemistry
1H,
13C and
31P NMR were recorded using Varian Inova 400
or Inova 500 instruments. All signals were referenced to TMS
(0.00 ppm), external 85% H3PO4/D2O (0.00 ppm) for
31P NMR,
or solvent peaks (CDCl3: d 7.26 ppm for
1H or 77.16 ppm for
13C;
D2O: d 4.80 ppm for
1H or TMS 0.00 ppm for
13C; d4-MeOH: d
3.49 ppm for
1H or 49.0 ppm for
13C). Melting points were
obtained using a Reichert-Jung hot-stage apparatus. LC-MS
spectra were obtained using an Agilent 6220 dual-ESI-TOF
equipped with an 1100 series autosampler, all runs were
conducted with 0.1% formic acid. TLC analysis used alumini-
um-backed Merck Silica Gel 60 F254 sheets, with detection using
UV light, 2% KMnO4 in H2O, ninhydrin, vanillin, 5% H2SO4 in
MeOH, orcinol in 5% H2SO4 in MeOH, or cerium molybdate
(‘‘Hanessian’s stain’’) with heating as necessary. Flash chromatog-
raphy was performed using Geduran silica gel according to the
method of Still et al. [49] HPLC was performed using Agilent
instruments, Synergi 4 mm Hydro-RP 80A columns were used for
preparative runs, and ProteCol C18 HQ305 or Supelco Discovery
C18, 15 cm64.6 mm 5 mm columns were used for all analytical
Leishmania b-1,2-Mannosyltransferase Inhibitors
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eluent for all HPLC runs unless otherwise noted. Dry CH2Cl2,
THF, and Et2O were obtained from a solvent drying apparatus
(Glass Contour of SG Water, Nashua, U.S.A.). DMF was dried
over 4 A ˚ molecular sieves.
29,39-Di-O-(t-butyldimethylsilyl)-59-O-(2-cyanoethyl-N,N-
diisopropylphosphoramidityl) guanosine 3. Diisopropyla-
mmonium tetrazolide (108 mg, 0.631 mmol) was added to a
stirring mixture of the alcohol 2 (269 mg, 0.53 mmol) and
(
iPr2N)2POCH2CH2CN (184 mL, 0.58 mmol) in CH2Cl2 (7 mL)
at 0uC under N2. The mixture was warmed to rt and allowed to
stir for 75 min before the addition of sat. aq. NaHCO3. The
mixture was extracted with CH2Cl2 (46) and the organic phase
was washed with sat. aq. NaCl, dried (Na2SO4), filtered and
concentrated under reduced pressure. The crude material was
purified by flash chromatography (99:1 EtOAc/Et3NR94:5:1
EtOAc/MeOH/Et3N) to give the phosphoramidite 3 (171.5 mg,
46%) as an approximately 1:1 mixture of diastereomers.
31P NMR
(202.5 MHz, CDCl3) d 149.25, 149.62 (Figure S2); lit. [30]
31P
NMR (121 MHz, (CD3)2CO) d 148.8.
29,39-Di-O-(t-butyldimethylsilyl)-59-O-(2-cyanoethylpro-
pargylphospho)guanosine 4. As o l u t i o no f1 H-tetrazole
(20.2 mg, 0.290 mmol) and the phosphoramidite 3 (171 mg,
0.241 mmol) in dry CH2Cl2 (7.2 mL) under N2 was stirred at rt
for 15 min then cooled to 0uC before propargyl alcohol (82 mL,
3.53 M in CH2Cl2) was added. After 10 min the solution was
b r o u g h tt or ta n da l l o w e dt os t i rf o raf u r t h e r1 5m i n .T h ec r u d e
phosphite ester was oxidized by the dropwise addition of I2 in
H2O/pyridine/THF (2.54 mL, 0.10 M, 2:20:80). Stirring was
continued for a further 10 min before the addition of CH2Cl2
(10 mL) and enough 0.1 M aq. Na2SO3 to neutralize any
remaining I2. The organic phase was washed sequentially with
Figure 4. First-round screening of combinatorial library as inhibitors of extension of octyl a-D-mannopyranoside by L. mexicana
Dgmp cell membranes containing b-1,2-mannosyltransferase. Assay conditions: 40 mM octyl a-D-mannopyranoside, 50 mM GDP-[
3H]mannose,
inhibitors at 4 mM, 15 min, 27uC. TLCs were developed in ‘‘solvent A’’. ‘‘-ve’’ indicates reaction mixture that does not contain any inhibitor. M2–5
denote the oligomer length of oligomannosides formed from the substrate.
doi:10.1371/journal.pone.0032642.g004
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concentrated under reduced pressure. The crude material was
purified by flash chromatography (100% EtOAcR27:2:1
EtOAc/MeOH/H2O) to afford the phosphate triester 4 as a
colourless solid (93.8 mg, 57%).
31P NMR (202 MHz, CDCl3) d
–0.82 (Figure S3); HRMS (ESI
+): m/z 683.2809 [M+H]
+ (calcd.
[C28H47N6O8Si2P+H]
+ 683.2804).
Sodium 59-O-(propargylphospho)guanosine 5. The
phosphate triester 4 (26.5 mg, 0.039 mmol) was dissolved in
1.0 M TBAF/THF (100 mL) and the mixture was stirred at rt for
45 min. EtOAc (5 mL) was added and the mixture washed
sequentially with H2O( 3 6), brine, dried (Na2SO4), filtered and
concentrated under reduced pressure. The crude residue was
dissolved in 15% MeCN/H2O and eluted through a C18 cartridge
(15R30% MeCN/H2O). Fractions containing product were
combined and concentrated under reduced pressure. The
residue was purified by preparative HPLC (
iPrOH/H2O with
0.1% TFA), and then dissolved in H2O and eluted through a
column of Dowex 50W-X4 cation-exchange resin (Na
+ form), then
concentrated to give the alkyne 5 as the sodium salt (6.0 mg, 37%,
.98% pure by HPLC 254 nm), m.p. 164–166uC; [a]D
19 –5u (c
1.00, H2O);
1H NMR (500 MHz, D2O) d 2.88 (1 H, t, J 2.4 Hz,
CH2CCH), 4.15–4.20 (1 H, ddd, J49,59a 3.0, J59a,59b 11.9,
3JP,H
5.1 Hz, H59a), 4.25–4.30 (1 H, ddd, J49,59b 2.5, J59a,59b 11.9,
3JP,H
4.5 Hz, H59b), 4.41 (1 H, m, H49), 4.49–4.54 (3 H, m,
H39,CH2CCH), 4.76, (1 H, app t, H29), 6.07 (1 H, d, J1,2
3.7 Hz, H19), 8.96 (1H, s, H8) (Figure S4);
13C NMR (125 MHz,
D2O) d 53.60 (1 C, d,
2JC,P 4.7 Hz, CH2CCH), 64.19 (1 C, d,
2JC,P 5.3 Hz, C59), 69.46, 74.27, 75.64, 79.14, 83.97, 89.58 (6 C,
C19,29,39,49,CH2CCH), 108.93 (1 C, C5), 135.68, 149.64, 155.25,
155.31 (4 C, C2,4,6,8) (Figure S5);
31P NMR (202 MHz, D2O) d
5.97 (Figure S6); HRMS (ESI
+): m/z 402.0811 [M+H]
+ (calcd.
[C13H16N5O8P+H]
+ 402.0809), 424.0629 [M+Na]
+ (calcd.
[C13H16N5O8P+Na]
+ 424.0629). HPLC (254 nm): see Figure S7).
Protocol for library construction – Representative
example. An aqueous solution of 5 (1.75 mL, 0.50 M) was
added to a solution of azide A01 in DMSO (84 mL, 20.8 mM).
Copper filings (5 mg) and aq. CuSO4 (1.75 mL, 20 mM) were
added and the mixture was stirred for 36 h. In some instances it
was necessary to dilute reactions with additional DMSO to
redissolve the azide. After filtration by centrifugation (Nanosep,
Pall), the reaction vessel/filter cartridge was rinsed sequentially
with 20% DMSO/H2O, 50% DMSO/H2O, and 80% DMSO/
H2O. 1 mL was used for mass spectrometric analysis and the
combined mixtures were concentrated using a SpeediVac and
resuspended in 80% DMSO/H2O to obtain the 1,4-triazole stock
at a concentration of 25 mM. Reactions were analysed by LC-MS
(Zorbax XDB-C18) (see Table S1).
Resynthesis of triazole T47. A mixture of 5 (6.5 mg,
0.162 mmol) and A47 (7.1 mg, 0.186 mmol) were dissolved in
0.71 mM CuSO4 (1.0 mL, 9:1 DMSO/H2O), copper filings
(10 mg) were added and the mixture was stirred vigorously
overnight. The mixture was filtered under vacuum and loaded
onto a silica column, which was eluted with EtOAc/MeOH/H2O
(17:2:1R7:2:1). Fractions containing product were combined and
concentrated under reduced pressure. The residue was dissolved in
MeOH/H2O (1:1) and further purified by column chromatography
with Dowex 50W-X4 cation-exchange resin (Na
+). Product-
containing fractions were combined and subjected to reverse
phase chromatography (H2O/MeOH) to give the triazole T47 as
an orange solid (6.4 mg, 50%, .98% pure by HPLC 254 nm),
1H
NMR (500 MHz, D2O) d 4.01 (1 H, m, H59a), 4.11 (1 H, ddd,
J49,59b 3.3, J59a,59b 11.5,
3JP,H 5.2 Hz, H59b), 4.18 (1 H, br s, H49),
4.39 (2 H, s, CH2Bn), 4.41 (1 H, dd, J29,39 5.3, J39,49 3.7 Hz, H39),
4.49 (1 H, t, H29), 5.04 (1 H, dd,
2JH,H 13.2,
3JP,H 10.6 Hz,
CH2Ph), 5.10 (1 H, dd,
2JH,H 13.2,
3JP,H 8.9 Hz, CH2Ph), 6.07
(1 H,br s, H19), 7.15 (2 H,26CH2Ph),7.41 (3H,36CH2Ph), 7.63
(1 H,d, Ar), 7.73(1 H,m,Ar),7.79 (1 H,triazole),7.83 (1 H,m,Ar),
8.10 (2 H, m, Ar), 8.16 (1H, s, H8), 8.39 (1 H, d, Ar) (Figure S8);
13C
NMR (125 MHz, D2O) d 43.48 (1 C, CH2Ph), 58.85, 64.70, 70.05,
73.89, 83.44, 86.44 (6 C, C19,29,39,49,59,POCH2), 115.76(1 C, C5),
126.79, 126.84, 127.63, 127.73, 127.87, 128.74, 130.64, 131.28,
131.34, 132.78, 133.28, 134.91, 135.33, 136.77, 137.07, 140.59,
144.37, 144.42, 150.85, 153.51, 158.04, 166.24(25 C, C2,4,6,8,Ar),
181.16, 182.27 (2 C, 26 quinone C=O) (Figure S9);
31PN M R
(202 MHz, CDCl3) d 4.38 (Figure S10); HRMS (ESI
+): m/z
784.1865 [M+H]
+ (calcd. [C35H30N9O11P+H]
+ 784.1875),
Figure 5. Identification and characterization of T47. A) Second-
round screening of cherry-picked members of combinatorial library as
inhibitors of extension of octyl a-D-mannopyranoside by L. mexicana
Dgmp cell membranes containing b-1,2-mannosyltransferase. Assay
conditions: 40 mM octyl a-D-mannopyranoside, 50 mM GDP-[
3H]man-
nose, inhibitors at 1.27 mM, 15 min, 27uC. TLCs were developed in
‘‘solvent A’’. ‘‘-ve’’ indicates reaction mixture that does not contain any
inhibitor. M2,3 denote the oligomer length of oligomannosides formed
from the substrate. B) Comparative IC50 values of GMP and T47. Open
squares denote GMP, closed triangles denote T47.
doi:10.1371/journal.pone.0032642.g005
Figure 6. Structures of biphenyl-based mono/diphosphonu-
cleotide triazole adducts.
doi:10.1371/journal.pone.0032642.g006
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+ (calcd. [C35H30N9O11P+Na]
+ 806.1695).
HPLC (254 nm): see Figure S11.
2. Protocols for biochemical analysis
General methods. Hypotonic lysis buffer contains:
NaHEPES-NaOH (pH 7.4) 1 mM, EGTA 2 mM, DTT 2 mM
and protease inhibitor cocktail (p.i.c.) 40 mL/mL (complete,
EDTA-free, Roche catalogue no. 1873580). Low ionic strength
assay buffer contains: NaHEPES-NaOH (pH 7.4) 5 mM, MgCl2
5 mM, MnCl2 1 mM, DTT 1 mM, EGTA 2 mM and p.i.c.
40 mL/mL. ‘‘Hot labelling mix’’ contains: 0.25 mM GDP-
mannose containing GDP-[
3H]mannose (,15 million cpm/mL)
in low ionic strength assay buffer. All assays were carried out with
Triton X-100 at a final concentration of 0.1%. Scintillation
counting was performed using a TRI-CARB 2100TR
manufactured by Packard (Canberra, Australia). HPTLC
analysis was performed on silica gel 60 aluminium-backed sheets
(Merck). HPTLC ‘‘solvent A’’ contains CH3Cl:CH3OH:13 M
NH3:1 M NH4OAc:H2O (180:140:9:9:23 v/v). Radiolabelled
products were detected and quantified using a Bertold LB 2821
automatic linear scanner, then visualized by fluorography after
spraying plates with EN
3HANCE spray (PerkinElmer Life
Sciences) and exposure to Biomax MR film (Eastman Kodak
Co.) at 280uC.
Preparation of parasite membranes. L. mexicana Dgmp
promastigotes [6] were cultivated in RPMI medium supplemented
with 10% heat-inactivated fetal bovine serum at 27uC. Stationary
phase promastigotes (day 5 culture) were centrifuged (10 min,
2000 rpm @ 25uC) and the supernatant discarded. The cells were
resuspended in PBS to a concentration of 4.0610
7 cells mL
21 and
divided into 1.0 mL aliquots. After centrifugation (30 s,
13,200 rpm @ 25uC) the supernatants were discarded and
promastigote lysis induced by suspension of the pellet in chilled
hypotonic lysis buffer (50 mL) and incubation on ice for 10 min.
The preparations were centrifuged (5 min, 5,000 rpm @ 4uC) and
the crude microsomal pellet washed in low ionic strength assay
buffer (60 mL), centrifuged again, then resuspended in low ionic
strength assay buffer (60 mL) to give an approximate total volume
of 70 mL.
Kinetic analysis of GDP-mannose and octyl a-D-
mannopyranoside. Mannosyltransferase activity was assayed
by incubating L. mexicana Dgmp microsomes (70 mL in low ionic
strength assay buffer) with octyl a-D-mannopyranoside 1 (10 mL,
0.5 M) and GDP-[
3H]mannose (20 mL, 5.0 mM, with approx.
150,000 cpm/assay). The reactions were stopped at indicated
times by the addition of 200 mLH 2O-saturated butanol with
vortexing, and the upper butanol phase separated by
centrifugation and analyzed by HPTLC as described below.
The KM and Vmax values for GDP-mannose was determined by
incubating the lysates with 10 ml of 5.0 mM, 20 mM, 80 mM,
320 mM or 1.28 M GDP-mannose and 20 ml of 250 mM octyl a-
D-mannopyranoside 1 at 27uC for 2, 3, 5, or 7 min. Analysis of
data from experiments conducted at the three highest concentra-
tions gave approximate values of KM=1.0 mM and Vmax=
1.8 mMs
21 for GDP-mannose.
The KM and Vmax values for octyl a-D-mannopyranoside 1 was
determined by incubating lysates with 10 mL of 1.0 M, 200 mM,
40 mM, 8.0 mM, or 1.6 mM octyl a-D-mannopyranoside 1 and
GDP-[
3H]mannose (20 mL, 50 mM, approx. 150,000 cpm) at
27uC for 2, 4, 6 or 8 min. Analysis of data from experiments
conducted at the three highest concentrations gave approximate
values of KM=4.3 mM and Vmax=2.3 mMs
21 for octyl a-D-
mannopyranoside.
Analysis of radioactive products. Recovery of radiolabeled
product in the butanol phase was determined by scintillation
counting (2 mL aliquot). Butanol samples were subsequently dried
using a SpeediVac rotary vacuum concentration and resuspended
in 40% propanol (10 mL), then 361.5 mL of each sample was
loaded onto an HPTLC plate. Samples were developed in ‘‘solvent
A’’ and the products visualized and quantified as outlined in the
General Methods.
Screening of the combinatorial library for inhibitors of L.
mexicana b-1,2-mannosyltransferases. Triazoles T1–T47
(20 mL, 7.91 mM or 25 mM, in 80% DMSO) were individually
pre-incubated with L. mexicana Dgmp membranes (70 mL in low
ionic strength assay buffer), and octyl a-D-mannopyranoside
(10 mL, 0.5 mM), for 10 min on ice. ‘‘Hot labeling mix’’ (25 mL)
was added to each of the vessels and the reactions incubated at
27uC for 15 min. The reactions were stopped by the addition of
200 mLH 2O-saturated butanol followed immediately by
vortexing, sonication, and centrifugation (2 min, 13,200 rpm,
25uC). The butanol phases were transferred to new vessels and the
aqueous phases extracted with a further 26200 mL of butanol.
The combined organic phases were back-extracted with H2O
(200 mL). The butanol extracts were concentrated to dryness using
a SpeediVac rotary vacuum concentrator and resuspended in 40%
propanol (50 mL) by vortexing and sonication. Each sample
(361.5 mL) was loaded onto an HPTLC plate and the plates were
developed in ‘‘solvent A’’. Products were visualized and quantified
as outlined in the General Methods.
IC50 determination for T47 and GMP. Octyl a-D-
mannopyranoside 1 (5 mL, 340 mM) was incubated with L.
mexicana Dgmp cell membranes (70 mL in low ionic strength assay
buffer) for 5 min at 0uC. Solutions of inhibitor (20 mL of 56, 28, 14,
7.0, 3.5, 1.75, 0.875, or 0.438 mM) were added and the reactions
initiated by the addition of GDP-[
3H]mannose (5 mL, 70 mM,
approx. 150,000 cpm). After 4 min at 27uC the reactions were
stopped and prepared for HPTLC analysis as described above.
Supporting Information
Figure S1 Azides used in construction of the combina-
torial library. A01–A19 & A29 were synthesized as
previously reported [12]. All other azides depicted were
obtained commercially.
(TIF)
Figure S2
31P NMR spectrum of 29,39-di-O-(t-butyldi-
methylsilyl)-59-O-(2-cyanoethyl-N,N-diisopropylpho-
sphoramidityl) guanosine 3.
(TIF)
Figure S3
31P NMR spectrum of 29,39-di-O-(t-butyldi-
methylsilyl)-59-O-(2-cyanoethylpropargylphospho)gua-
nosine 4.
(TIF)
Figure S4
1H NMR spectrum of sodium 59-O-(propar-
gylphospho)guanosine 5.
(TIF)
Figure S5
13C NMR spectrum of sodium 59-O-(propar-
gylphospho)guanosine 5.
(TIF)
Figure S6
31P NMR spectrum of sodium 59-O-(propar-
gylphospho)guanosine 5.
(TIF)
Leishmania b-1,2-Mannosyltransferase Inhibitors
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32642Figure S7 HPLC chromatogram (254 nm) of sodium 59-
O-(propargylphospho)guanosine 5.
(TIF)
Figure S8
1H NMR spectrum of triazole T47.
(TIF)
Figure S9
13C NMR spectrum of triazole T47.
(TIF)
Figure S10
31P NMR spectrum of triazole T47.
(TIF)
Figure S11 HPLC chromatogram (254 nm) of triazole
T47.
(TIF)
Table S1 Calculated and observed m/z values for the
triazole library.
(DOC)
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